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The complement system is a key component of the host immune response for the 27 
recognition and clearance of Streptococcus pneumoniae. In this study, we have 28 
demonstrated that the amidase LytA, the main pneumococcal autolysin, inhibits 29 
complement-mediated immunity independent of effects on pneumolysin by a 30 
complex process of impaired complement activation, increased binding of 31 
complement regulators, and direct degradation of C3. The use of human sera 32 
depleted in either C1q or factor B confirmed that LytA prevented activation of 33 
both the classical and alternative pathways whereas pneumolysin only inhibited 34 
the classical pathway. LytA prevented binding of C1q and the acute phase protein 35 
CRP to S. pneumoniae, thereby reducing activation of the classical pathway on the 36 
bacterial surface. In addition, LytA increased recruitment of the complement 37 
down-regulators C4BP and factor H to the pneumococcal cell wall and directly 38 
cleaved C3b and iC3b to generate degradation products. As a consequence, C3b 39 
deposition and phagocytosis increased in the absence of LytA and were markedly 40 
enhanced for the double lytA ply mutant, confirming that a combination of LytA 41 
and Ply was essential for the establishment of pneumococcal pneumonia and sepsis 42 
in a murine model of infection. These data demonstrate LytA has pleiotropic 43 
effects on complement activation, which in combination with the effects of 44 
pneumolysin on complement to assist pneumococcal complement evasion confirm a 45 
major role of both proteins for the full virulence of the microorganism during 46 
septicemia. 47 
 48 




Streptococcus pneumoniae (also termed the pneumococcus) colonizes the human 51 
nasopharynx in a high percentage of the population and can be carried asymptomatically 52 
from the first days of life (1). S. pneumoniae is the most common etiologic agent of 53 
acute otitis media, community acquired pneumonia and a major cause of bacterial sepsis 54 
and meningitis resulting in significant rates of morbidity and mortality worldwide (2). 55 
Prevention of pneumococcal disease requires efficient recognition and clearance of the 56 
invading pathogen by the complement system and professional phagocytes (3, 4). 57 
Activation of the three complement cascades —termed the classical (CP), the alternative 58 
(AP) and the lectin pathways− leads to the formation of the key complement component 59 
C3b that plays a pivotal role in the host immune response such as opsonization and 60 
clearance of invading pathogens (5-7). The CP is important for complement recognition 61 
of pneumococci and is generally activated by the recognition of antigen-antibody 62 
complexes on the bacterial surface (6, 8) as part of the adaptive immune response, and 63 
by natural IgM, the lectin SIGN-R1 and acute phase proteins as part of the innate 64 
immune response (6, 9, 10). In addition, the AP is activated by the spontaneous 65 
hydrolysis of the C3 component, triggering the amplification of C3 deposition (11, 12), 66 
and mannose binding lectin pathway activation has also been recently reported for S. 67 
pneumoniae (7). A finely controlled set of specific surface-bound and fluid-phase 68 
regulators such as C4 binding protein (C4BP) and factor H (FH) protect host cells from 69 
complement activation and complement-mediated damage (13-18).  70 
Although the expression of S. pneumoniae capsule is essential for the virulence of 71 
the microorganism, numerous pneumococcal proteins also contribute to pathogenesis 72 
including by promoting complement evasion (3, 19). For example, the S. pneumoniae 73 
cell wall protein PspC can recruit the complement down-regulators C4b-binding protein 74 
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(C4BP) and factor H (FH) to the bacterial cell surface, thereby inhibiting activation of 75 
the CP and AP respectively (13-18). In addition, the cholesterol-dependent cytolysin 76 
pneumolysin (Ply) (20) prevents CP mediated complement recognition of pneumococci 77 
through interactions with the CP component C1q (3, 21). However, export of Ply into 78 
extracellular fluid or for attachment to the cell wall seems to require lysis of the bacteria 79 
(22). The pneumococcal protein involved in lysis is the major autolytic enzyme of the 80 
bacterium, termed LytA, an amidase that cleaves the N-acetylmuramoyl-L-alanine 81 
bonds of pneumococcal peptidoglycan (23). Previously, LytA is thought to contribute 82 
towards pneumococcal pathogenesis due to its importance for the release of Ply and 83 
inflammatory mediators such as teichoic acids and peptidoglycan fragments from S. 84 
pneumoniae (23, 24) rather than direct effects on immune evasion independent of Ply.  85 
In this study we have investigated the contribution of Ply and LytA to the 86 
establishment of invasive pneumococcal disease (IPD) exploring their role in essential 87 
aspects of the pathogenesis process including evasion of different components of the 88 
host immune response. 89 
 90 
MATERIALS AND METHODS 91 
Bacterial strains and growth conditions. S. pneumoniae clinical isolates used were 92 
D39 [NCTC 07466, serotype 2 (ST2)], strain S3 lytA (ST23F) and its complemented 93 
mutant S3C (lytA+) (25) and strain 1515/97 (ST6B) and its lytA deficient strain (26). 94 
Isogenic D39 mutants in lytA, ply, pspC, or lytB were constructed by transformation 95 
with DNA prepared from mutants previously characterized and using standard protocols 96 
(18, 21, 27, 28). Pneumococcal strains expressing the green fluorescent protein (GFP) 97 
were constructed by genetic transformation with pMV158GFP (tetracycline resistant) as 98 
previously described (28). Kanamycin (250 μg/ml), erythromycin (0.2 μg/ml) and 99 
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tetracycline (0.5 μg/ml) were added to blood agar plates for isolation of bacterial 100 
transformants. S. pneumoniae strains were cultured on blood agar plates at 37°C in a 101 
CO2 atmosphere, or in Todd-Hewitt broth supplemented with 0.5% yeast extract, to an 102 
optical density at 550 nm (OD550) of 0.5, and stored at −70°C in 10% glycerol as single 103 
use aliquots.  104 
Binding of complement factors to S. pneumoniae. A pool of human sera from five 105 
healthy male volunteers unvaccinated against S. pneumoniae (median age: 40 years) 106 
were obtained with informed consent according to institutional guidelines and stored as 107 
single-use aliquots at −70°C as a source of complement and serum components. C1q, 108 
C3b, FH, C4BP and C-reactive protein (CRP) were assessed using flow cytometry 109 
assays as previously described (10, 18, 28). Human sera depleted in C1q and factor B 110 
were purchased from Calbiochem. C3b deposition was detected by incubating 5×106 111 
CFU of the bacteria opsonized with 20% serum using a fluorescein isothiocyanate 112 
(FITC)-conjugated polyclonal goat anti-human C3b antibody (ICN-Cappel) diluted 113 
1/300 in PBS/0.1% Tween-20. After incubation, the bacteria were washed with PBS-114 
Tween 20 (0.02%) to remove unbound components, fixed in 3% paraformaldehyde and 115 
analyzed on a FACS Calibur flow cytometer (BD Biosciences) or a Beckman-Coulter 116 
Cytomics FC500 using forward and side scatter parameters to gate on at least 25,000 117 
bacteria. The results were expressed as a relative percent fluorescence index (FI) that 118 
measures not only the proportion of fluorescent bacteria positive for the host serum 119 
component investigated but also the intensity of fluorescence that quantify the immune 120 
component bound (8). This assay was adapted to assess the binding to C1q, CRP, FH 121 
and C4BP using a conjugated polyclonal sheep anti-human C1q antibody (Serotec), a 122 
polyclonal rabbit anti-human CRP antibody (Calbiochem), a polyclonal sheep anti-123 
human FH antibody (Serotec) and a polyclonal sheep anti-human C4BP antibody 124 
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(Serotec). To detect CRP, FH and C4BP a secondary staining in PBS/0.1% Tween 20 125 
containing FITC-conjugated polyclonal goat anti-rabbit or FITC/DYLIGHT 649 anti-126 
sheep antibodies (Serotec) was performed. Direct interaction between purified LytA and 127 
purified C4BP or FH were performed by ELISA as previously described (10). Briefly, 128 
NUNC maxysorp 96-well plates were coated with 10 μg/ml of purified LytA for 2 h at 129 
37°C and blocked with a PBS-BSA 2% solution before 50 μl of different concentrations 130 
of purified human C4BP or FH were added to each well. After 2h incubation at 37°C, 131 
plates were incubated with 50 μl of sheep anti-human C4BP or FH (Serotec) diluted 132 
1/2000 in PBS. Finally, plates were incubated with 50 μl of rabbit anti-sheep HRP 133 
antibody (Santa Cruz) for 30 min and developed using o-phenylenediamine (Sigma 134 
Aldrich) before determining the OD492 using a microtiter plate reader (Anthos 2020).  135 
Quantification of phosphorylcholine and PspC. The level of phosphorylcholine 136 
(Pcho) and PspC on the bacterial surface was detected by flow cytometry as previously 137 
described (28). The conditions of the assays were the same as those described above for 138 
complement components except that bacterial strains were incubated for 1 h at 37°C 139 
with TEPC-15 antibody (a monoclonal antibody specific for Pcho, Sigma-Aldrich) 140 
diluted 1/25 or rabbit polyclonal antibody to PspC diluted 1/300 (a kind gift from Sven 141 
Hammerschmidt, University of Greifswald, Germany). The secondary antibodies used 142 
were rabbit anti-mouse FITC (Serotec) and goat anti-rabbit FITC (Serotec) for the 143 
detection of Pcho and PspC, respectively. 144 
C3b/iC3b degradation by LytA. Purified LytA (displaying amidase activity), the 145 
carboxy-terminal moiety or (choline-binding domain) of LytA (C-LytA) and the 146 
enzymatically inactive LytAH133A protein ⎯a mutated LytA amidase containing a 147 
His133→Ala substitution that inactivates the enzyme (29)— were obtained by 148 
overexpression of previously described plasmids in Escherichia coli (30). A lytA-149 
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deficient strain was opsonized for 20 min with human serum and after two washes with 150 
PBS/Tween-20, proteins were added and the C3b level was explored by flow cytometry. 151 
To detect C3 fragments by Western-blotting, a lytA null strain was opsonized with 50% 152 
human serum as a source of C3b in the absence or in the presence of different 153 
pneumococcal proteins (LytA, C-LytA, LytAH133A, or the LytC lysozyme) for 2 h at 154 
37°C. A sample of each supernatant was analyzed by 15% sodium dodecyl sulfate-155 
polyacrylamide gel electrophoresis (SDS-PAGE), the proteins were transferred to a 156 
membrane and fragments were revealed by immunoblotting using a goat anti-human 157 
C3b antibody. As controls, purified C3b protein with or without treatment with FH and 158 
factor I were included. Additionally, purified C3b and iC3b proteins (3 μg) in sodium 159 
phosphate buffer (20 mM. pH 6.9), were treated with 3 ng of LytA or LytAH133A and 160 
incubated for 2 h at 37°C. Samples were analyzed by SDS-PAGE using tricine instead 161 
of Tris-glicine (31, 32). 162 
Interaction of S. pneumoniae with phagocytes. Experiments investigating the 163 
recognition and phagocytosis by alveolar macrophages (AMs) were performed as 164 
previously described (27, 33). Briefly, murine MH-S cells (CRL-2019; ATCC) as AMs 165 
were grown in RPMI tissue culture medium supplemented with 10% heat-inactivated 166 
fetal calf serum and HEPES (10 mM). To test the recognition of the wild-type and the 167 
different mutants by AMs, cells (seeded in 24-well plates containing 7 × 105 cells per 168 
well) were infected in triplicate with 50 μl of a suspension of the pneumococcal strains 169 
at a ratio of 50 bacteria:1 cell and incubated at 37°C. For adhesion assays, cells were 170 
infected for 1 h, washed five times with PBS and lysed with 300 μl of a solution 171 
containing 0.025% saponin-PBS for 10 min. For phagocytosis assays, cells previously 172 
infected for 1 h were washed five times with PBS and incubated for an additional hour 173 
in tissue culture medium containing penicillin (10 μg/ml) and gentamicin (200 μg/ml) to 174 
8 
 
kill extracellular bacteria. Viable bacteria recovered from infected cells were obtained 175 
by plating serial dilutions on blood agar plates.  176 
Phagocytosis by neutrophils was evaluated using HL-60 cells (CCL-240; ATCC) 177 
differentiated to granulocytes and the general conditions of the assay were based on 178 
those described previously (10, 27, 34). Briefly, S. pneumoniae strains were 179 
fluorescently labeled by incubation with FAM-succinimidyl ester (FAM-SE, Molecular 180 
Probes) solution (10 mg/ml in dimethyl sulfoxide; Sigma-Aldrich) in 0.1 M sodium 181 
bicarbonate buffer for 1 h at 37°C, then washed six times with HBSS-0.2% BSA and 182 
stored in aliquots at −70°C in 10% glycerol for further assays. Infection assays were 183 
performed with a ratio of 10 bacteria per cell. A minimum of 6,000 cells were analyzed 184 
using a Cytomics flow cytometer. Results were expressed as a relative % phagocytosis 185 
index defined as the proportion of positive cells for fluorescent bacteria multiplied by 186 
the geometric mean of fluorescence intensity which correlates with the amount of 187 
bacteria phagocytosed per cell (8, 10, 27). 188 
Confocal microscopy. S. pneumoniae strains expressing the GFP were obtained by 189 
transformation with pMV158GFP and were used for immunofluorescence microscopy. 190 
MH-S cells and HL-60 cells previously infected as described above were seeded on 12-191 
mm circular coverslips for immunofluorescence staining. As HL-60 cells are in 192 
suspension, cells were centrifuged at 70 × g for 2 min using a Cytospin centrifuge 193 
(Thermo Electron, Pittsburgh, PA). For the detection of late endosomal markers in AMs 194 
we stained late antigen membrane proteins 1 or 2 (LAMP1, LAMP2). Coverslips 195 
containing the infected cells were washed twice in PBS containing 0.1% saponin (in 196 
PBS) and once in PBS and incubated for 30 min with primary antibodies. Staining was 197 
performed in PBS containing 10% horse serum, 0.1% saponin and the primary 198 
antibodies using a rat anti-mouse LAMP1 or LAMP2 (Southern Biotech) diluted 1/200, 199 
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and the DNA was stained with Hoechst (Invitrogen) diluted 1/2500. After 30 min 200 
incubation with primary antibodies at room temperature, coverslips were washed twice 201 
with PBS-saponin 0.1%, and once with PBS pH 7.0 before incubation during 30 202 
minutes at room temperature with a dilution 1/200 of the secondary antibody goat anti-203 
rat TRITC (Serotec). Actin cytoskeleton was stained with rhodamine-phalloidin 204 
(Invitrogen) diluted 1:200. Finally, coverslips were washed twice in PBS containing 205 
0.1% saponin, once in PBS, and once in H2O, mounted with Aqua Poly/Mount 206 
(Polysciences), and analyzed with a Leica spectral SP5 confocal microscope using the 207 
Leica software (LAS-AF). 208 
Experimental models of infection. C57BL/6 mice were bred by CIB-CSIC and 209 
ISCIII animal facilities. All mice used were 8–16 weeks old, and within each 210 
experiment, groups of mice were matched for age and sex. Studies investigating the role 211 
of Ply and LytA in the establishment of pneumococcal sepsis and pneumonia, groups of 212 
5 mice were infected as previously described (10). Briefly, for the sepsis model of 213 
infection, mice were challenged with 1×106 CFU/ml of each strain (in a volume of 200 214 
µl) by the intraperitoneal route, whereas for pneumonia mice under anesthesia with 215 
isofluorane were inoculated intranasally with 50 µl containing 107 CFU/mouse. At 24 h 216 
after challenge, a lethal dose of pentobarbital was administered and bacterial counts 217 
were determined from samples recovered from bronchoalveolar lavage (BAL), lung and 218 
blood. Experiments were repeated twice using 5 mice in each group and results were 219 
expressed as Log CFU/ml of bacteria recovered from the different sites. All animal 220 
procedures were approved by the Animal Care and Use Committees of CIB-CSIC and 221 
ISCIII (approval references CIB-FJD 06010017 and CBBA-PA 52_2011-v2). 222 
Quantification of capsular polysaccharide. Serotype 2 pneumococcal capsular 223 
polysaccharide (CPS) was either purchased from the American Type Culture Collection 224 
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(ATCC) or prepared as previously described (35). Glucuronic acid was determined with 225 
m-hydroxydiphenyl, as previously described (36) using type 2 CPS as standard and 226 
measuring the OD520 using a microtiter plate reader (Anthos 2020). Recognition of CPS 227 
of serotype 2 by specific antibodies was studied by a flow cytometry assay explained 228 
above using the wild-type D39 strain and the isogenic lytA mutant strain. The antibodies 229 
used for the detection were rabbit anti-serotype 2 (Statens Serum Institut) diluted 1/200 230 
and a secondary goat anti-rabbit FITC conjugated antibody (Santa Cruz) diluted 1/300. 231 
Results were expressed as a fluorescence index explained above. 232 
Statistical analysis. Data are representative of results obtained from repeated 233 
independent experiments, and each point represents the mean and standard deviations 234 
(SD) for 3 to 5 replicates. Statistical analysis was performed by using two-tailed 235 
Student’s t test (for two groups), whereas analysis of variance (ANOVA) followed by a 236 
Dunnett’s post hoc test were chosen for multiple comparisons. GraphPad InStat version 237 
5.0 (GraphPad Software, San Diego, CA) was used for statistical analysis. Differences 238 
were considered statistically significant with P <0.05 (*) and highly significant with P 239 
<0.01 (**) and P <0.001 (***). 240 
 241 
RESULTS 242 
Ply and LytA divert C3b deposition following a cooperative strategy. The 243 
complement system is an efficient immune surveillance system detecting foreign 244 
intruders and is one of the first lines of the host immune defense against S. pneumoniae 245 
(11). To identify the role of Ply and LytA in subversion of pneumococcal recognition by 246 
the key complement component C3b, strains defective in Ply and LytA were 247 
constructed. Strains lacking either LytA or Ply had increased C3b deposition on the 248 
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bacterial surface compared to the wild-type strain. Higher levels of C3b were found on 249 
the lytA mutant than on the ply defective strain, suggesting that LytA might avoid the 250 
recognition by C3b using a Ply-independent mechanism (Fig. 1A and B). Binding to 251 
C3b was even more pronounced for the double mutant lytA ply indicating that both 252 
proteins might act in concert avoiding complement mediated immunity (Fig. 1A and B). 253 
Incubation with human sera depleted in complement components C1q or factor B (CP 254 
or AP activity abolished respectively) confirmed that the presence of Ply only reduced 255 
the activation of the CP whereas the presence of LytA inhibited activation of both 256 
complement pathways, providing additional evidence that LytA impairs complement 257 
activation independently of Ply (Fig. 1C). Lack of enhanced C3b deposition when the 258 
double mutant lytA ply was incubated in C1q- or factor B-depleted sera, confirmed that 259 
the activity of both cascades was essential for the improved effect in complement 260 
evasion mediated by both proteins (Fig. 1).  261 
To exclude the possibility that cellular morphology (i.e., chain formation) might 262 
affect complement interaction, C3b deposition was analyzed on an isogenic lytB mutant 263 
strain, which forms long chains of bacteria (Fig. 1D and E). There was no increase in 264 
complement deposition on the lytB mutant, suggesting that at least, under our 265 
experimental conditions the increased C3b levels on the lytA null strain were not due to 266 
differences in cell separation (Fig 1). The capsule is known to inhibit complement 267 
activity against the pneumococcus (19), but the content of glucuronic acid (a component 268 
of the CPS of serotype 2) was actually higher for the lytA mutant strain (0.185 for wild-269 
type strain vs. 0.361 for the lytA mutant). In addition, the recognition of S. pneumoniae 270 
by specific antibodies to serotype 2 increased in the absence of LytA (100 ± 17 for wild-271 
type strain vs. 201 ± 121 for the lytA mutant, P<0. 05). These results suggest that the 272 
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increased C3b observed in the lytA null strain cannot be due to reduced levels of CPS 273 
expression by the lytA mutant. 274 
Ply and LytA prevent the activation of the classical pathway on S. pneumoniae. 275 
Activation of the CP by binding of C1q or acute phase proteins such as CRP or SAP to 276 
the bacterium is essential for complement-mediated immunity against S. pneumoniae 277 
whereas bacterial components impairing activation are critical factors for immune 278 
evasion (6, 10, 37). Hence, we investigated the effect of deposition of C1q or CRP on 279 
the bacterial surface using pneumococcal strains lacking Ply, LytA or both proteins 280 
simultaneously. S. pneumoniae defective in either Ply or LytA, showed higher levels of 281 
C1q binding confirming that both proteins allow S. pneumoniae to impair the activation 282 
of the CP (Fig. 2A and B). This effect was more pronounced in the absence of LytA 283 
suggesting that this amidase assists pneumococcal evasion of the CP activation using a 284 
Ply-independent strategy (Fig. 2A and B). CRP deposition was also increased in the 285 
absence of LytA but not Ply (Fig. 2C and D). These results together demonstrated that 286 
LytA is more effective than Ply at impairing CP activation. As the increased levels of 287 
CRP on the lytA mutant might be due to differences in the amount of Pcho residues 288 
exposed on the bacterial cell wall, the level of Pcho was measured using pneumococcal 289 
strains of two different serotypes and the corresponding isogenic lytA mutants. Lack of 290 
LytA was associated with increased detection of Pcho, indicating that LytA impaired 291 
recognition of pneumococci by the CP through effects on the availability of Pcho for 292 
binding to CRP (Figs. 2E−G).  293 
LytA avoids complement immunity by recruiting fluid-phase down-regulators. 294 
To prevent damage of host cells by a constant low level of complement activation, a 295 
finely controlled set of soluble and membrane-bound regulators allow that any 296 
complement activation on host cells is either avoided or strongly inhibited (11). 297 
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Trapping fluid-phase down-regulators such as C4BP and FH by certain pathogens is a 298 
successful strategy for avoiding the complement response (13). Binding of the CP 299 
inhibitor protein C4BP was greatly reduced in the lytA null strain (Fig. 3A and B). As 300 
PspC has been recently reported as a ligand for C4BP and FH, an isogenic pspC mutant 301 
strain was investigated (15, 17, 18). Loss of PspC resulted in a reduced proportion of 302 
C4BP binding with similar levels to those found in the absence of LytA, whereas loss of 303 
both PspC and LytA showed greater reduction in C4BP binding, demonstrating that 304 
both proteins play a key role in the recruitment of C4BP (Fig. 3A and B). Fluorescence 305 
intensity values also confirmed that lack of either LytA or PspC was significantly 306 
associated with impaired recruitment of C4BP (23 ± 5 for the wild-type strain, 17 ± 2 307 
for the ply strain, 8 ± 2 for the lytA strain, 9 ± 1 for the pspC strain and 6 ± 1 for the 308 
pspC lytA strain). To confirm the requirement of LytA for binding to C4BP, the C4BP 309 
binding assays were performed using a serotype 23F isolate lytA mutant strain (termed 310 
S3, the first described clinical isolate of S. pneumoniae deficient in LytA activity) and 311 
the corresponding lytA+ transformant (25) (termed S3C) (Fig. 3C and D). Loss of LytA 312 
in strain S3 was again associated with reduced C4BP binding which was restored by 313 
transformation with the lytA+ allele (strain S3C), confirming that LytA is a novel ligand 314 
of S. pneumoniae for C4BP (Fig. 3C and D). Direct binding of purified LytA with 315 
different concentrations of purified human C4BP was observed, supporting a role for 316 
LytA in recruiting C4BP to the bacterial cell surface (Fig. 3F).  317 
Interaction with FH, the down-regulator of the AP, was also evaluated for the 318 
different strains. As expected, lack of Ply did not affect FH binding, whereas loss of 319 
LytA or PspC produced significantly lower levels of FH bound than those found with 320 
the wild-type strain (Fig. 4A and B). In addition, binding of FH to the double mutant 321 
pspC lytA was markedly impaired indicating that both proteins are important 322 
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pneumococcal ligands for FH binding (Fig. 4A and B). Fluorescence intensity values 323 
confirmed that lack of either LytA or PspC on the D39 strain was significantly 324 
associated with impaired binding to FH (72 ± 30 for the wild-type strain, 58 ± 10 for the 325 
ply strain, 23 ± 7 for the lytA strain, 5 ± 1 for the pspC strain and 5 ± 1 for the pspC lytA 326 
strain). Recruitment of FH was also evaluated for the strains S3 and S3C of serotype 327 
23F (Fig. 4C−E). The proportion of bacteria binding to FH was similar between both 328 
strains (Fig. 4C), but the intensity of the FH bound was significantly lower in the 329 
absence of LytA (Fig. 4D and E) further supporting a role for LytA in pneumococcal 330 
recruitment of high levels of FH. Furthermore, a direct interaction between purified 331 
LytA autolysin and human FH proteins was observed (Fig. 4F). There were no 332 
differences in the level of PspC measured between the wild-type and the lytA-deficient 333 
strains (Fig. 5), confirming that the reduced levels of both C4BP and FH on the lytA-334 
deficient strain were not caused by effects of the lytA mutation on PspC expression (28). 335 
LytA impairs opsonization by degradation of C3b and iC3b. Proteolytic enzymes 336 
can counteract the effects of complement activation by bacterial pathogens (13). Hence, 337 
the ability of LytA to cleave the C3b deposited on the bacterial surface and purified 338 
C3b/iC3b components were investigated (Fig. 6). For these experiments we used a fully 339 
active LytA protein (LytA), its C-terminal domain (C-LytA), and the enzymatically 340 
inactive protein LytAH133A (see above). Degradation of C3b deposited was initially 341 
investigated by adding the different LytA proteins to a previously opsonized lytA-342 
deficient strain (Fig. 6A). The results demonstrated full restoration of the wild-type 343 
phenotype only when the fully active LytA amidase was used (Fig. 6A). This result was 344 
confirmed by Western-blotting using an anti-C3 antibody. A C3 fragment of small size 345 
was observed after addition of the LytA protein but not after addition of LytAH133A, C-346 
LytA, or the LytC lysozyme (Fig. 6B). C3b degradation products were also found when 347 
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LytA was incubated with either C3b (Fig. 6C) or iC3b (Fig. 6D), confirming direct 348 
cleavage of C3b and iC3b components by LytA. Degradation of the C3b/iC3b deposited 349 
on the surface of the non-encapsulated R6 strain was also observed, indicating that 350 
LytA is involved in C3 degradation independently of capsule expression (Fig. 6E). 351 
These results demonstrated that the pneumococcal LytA autolysin can cause 352 
degradation of the complement components C3b and iC3b, partially explaining why the 353 
lytA-deficient strain had higher levels of opsonization with C3b/iC3b. 354 
 355 
LytA and Ply divert phagocytosis by professional phagocytes. Neutrophils control 356 
pneumococcal dissemination by phagocytosis, a process that requires opsonization of 357 
bacteria by the complement system (38, 39). Opsonization with Hanks balance salt 358 
solution (HBSS) or heat-killed human serum (HKS) did not support phagocytosis of S. 359 
pneumoniae by human neutrophils whereas normal human serum did, confirming the 360 
importance of complement-mediated immunity for this process (Figs. 7A−C). There 361 
was increased phagocytosis of the lytA and ply mutants compared to the wild-type 362 
strain, showing that both proteins are important bacterial factors involved in evasion of 363 
phagocytosis. The lytA mutant exhibited higher phagocytosis levels than the ply mutant 364 
suggesting that LytA participates in resistance to phagocytosis by a mechanism that is 365 
independent of the release of Ply (Figs. 7A−C). Moreover, synergistic increases in 366 
phagocytosis were found for the double lytA ply mutant in comparison to the single 367 
mutants and the wild-type strain, demonstrating that both proteins contribute to evasion 368 
of phagocytosis by neutrophils (Figs. 7A−C).  369 
Adhesion to a murine cell line of AMs was slightly increased in the absence of Ply or 370 
LytA and markedly increased in the double mutant suggesting that these two proteins 371 
enable S. pneumoniae to divert the recognition by AMs (Fig. 7D). Time course 372 
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experiments were performed to evaluate the phagocytosis process within the 373 
macrophage. At an early phase, phagocytosis of the ply and lytA single mutants was 374 
increased (Fig. 7A). Phagocytosis of the double ply and lytA mutant strain was more 375 
efficient in comparison to the single mutants confirming the additive effect of loss of 376 
these two proteins on pneumococcal phagocytosis by AMs (Fig. 7E). Compared with 1 377 
h, bacterial load was significantly reduced over time with more than 100-fold reduction 378 
at 4 h suggesting that once the macrophage has recognized and phagocytosed 379 
pneumococcal strains lacking Ply and LytA, the machinery of the macrophage 380 
efficiently destroys the engulfed bacteria (Fig. 7F). To confirm this possibility, we 381 
investigated maturation of the phagosome containing the lytA ply null strain using 382 
immunofluorescence microscopy to analyze colocalization of phagocytosed GFP-383 
expressing bacteria with early and late endosomal markers. The double mutant was 384 
observed in LAMP1- and LAMP2- positive compartments (Fig. 7G) suggesting that in 385 
the absence of Ply and LytA, AMs efficiently process S. pneumoniae by the 386 
conventional phagolysosomal pathway. 387 
 388 
LytA and Ply enhance the establishment of pneumococcal pneumonia and 389 
invasive disease. Mouse models of pneumonia and sepsis were used to characterize the 390 
contribution of Ply and LytA to the pathogenesis of S. pneumoniae. Lack of either Ply 391 
or LytA was associated with a significant attenuation in the sepsis model in comparison 392 
to the wild-type strain (Fig. 8). In addition, virulence of the lytA ply double mutant was 393 
greatly reduced compared to the single mutants and the wild-type strain, confirming that 394 
both proteins contribute separately to the establishment of pneumococcal sepsis (Fig. 395 
8A).  396 
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In the pneumonia model, the levels of ply or lytA single mutants recovered from 397 
BAL, lung and blood samples were significantly lower than those obtained with the 398 
parental strain, indicating that both proteins are involved in the pathogenesis of 399 
pneumococcal pneumonia (Figs. 8B−D). Moreover, loss of both Ply and LytA had a 400 
caused further falls in CFU recovered from BAL, lung and blood samples confirming 401 
that the activity of both proteins is required for the full virulence of the bacterium in the 402 
respiratory tract, and for spread from the lung to the blood (Figs. 8B−D). These results 403 
are compatible with the complement interaction data and confirm that inhibition of 404 
complement deposition on S. pneumoniae by the combination of LytA and Ply is 405 
essential for full virulence during systemic infection. Collectively, these data suggest 406 
that the enhanced effect on virulence by LytA and Ply is mainly due to their combined 407 
inhibition of complement-dependent immunity and phagocytosis.  408 
DISCUSSION 409 
S. pneumoniae is the leading cause of community-acquired pneumonia and a major 410 
cause of sepsis and meningitis associated with high morbidity and mortality rates 411 
worldwide (2, 40). As one of the most devastating human pathogens, S. pneumoniae has 412 
developed a wide arsenal of virulence factors to escape the well-balanced machinery of 413 
the immune system (3). Several proteins are involved in the establishment of IPD that 414 
occurs when S. pneumoniae invades typically sterile sites causing bacteraemic 415 
pneumonia and sepsis or when it crosses the blood brain barrier causing meningitis (3). 416 
Ply is a cytolytic protein with a significant role in pneumonia, sepsis and meningitis but 417 
apparently not in carriage (3, 21, 24, 41-43). In contrast, the contribution of LytA to 418 
pneumococcal pathogenesis is poorly understood. The use of strains deficient in LytA 419 
has demonstrated attenuation of these mutants in different models of infection 420 
suggesting that LytA is important for virulence (39, 44, 45). Activation of complement-421 
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mediated immunity is an essential and critical component of the host immune response 422 
against S. pneumoniae (5-7, 9), and Ply has previously been reported to reduce the CP 423 
opsonic activity against S. pneumoniae. The effects of LytA on virulence has 424 
traditionally been linked to the release of Ply and not to a direct effect of LytA (3, 46, 425 
47). However, our results demonstrate that LytA plays a critical role in complement 426 
evasion that is independent of the release of Ply. The lytA mutant had greater levels of 427 
CRP, C1q and C3b binding to its surface than the ply mutant, and the double ply lytA 428 
mutant had increased C3b deposition compared to the single mutant strains confirming 429 
that both proteins confer complement resistance on S. pneumoniae. Our findings 430 
confirm previous data suggesting that Ply impairs the activation of the CP through C1q 431 
(21, 37, 46, 47) and this might be a possible explanation for the increased recognition 432 
by C1q in the absence of both Ply and LytA. Using a lytA mutant strain, other authors 433 
have reported increased sensitivity to complement-dependent clearance, and attributed 434 
this attenuation to its increased bacterial chain length suggesting that chain length is an 435 
important factor that increases the ability to fix complement C3b (39). Although a 436 
certain deficit in promoting efficient separation of daughter cells in the absence of LytA 437 
may increase the recognition by C3b, our results suggest that this is not the full 438 
explanation for increased complement activity against the lytA mutant as formation of 439 
longer chains by the lytB mutant strain does not affect complement deposition (27). 440 
Instead, the lytA mutation affects complement activity by a variety of mechanisms 441 
which led to increased CP and AP activity.  442 
One mechanism was in the lytA mutant an increased amount or accessibility on the 443 
cell surface of Pcho, the target for CRP, natural IgM and SAP binding to S. pneumoniae 444 
and therefore of innate CP activation. Modification of Pcho levels did not affect the 445 
expression of PspC, another important choline binding proteins involved in complement 446 
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evasion. Despite this, recruitment of the fluid-phase down-regulators C4BP and FH 447 
(which are both known to bind to PspC) were decreased in the lytA mutant, and assays 448 
using purified proteins demonstrated direct binding between LytA or C4BP and FH. 449 
Hence, our findings demonstrate that LytA is an additional pneumococcal protein that 450 
reduces complement-mediated immunity by recruiting C4BP and FH. Finally, we have 451 
shown evidence that LytA mediates the direct degradation of C3 by S. pneumoniae that 452 
has previously been described (48).  453 
Our data suggests that LytA can inhibit complement activation against S. 454 
pneumoniae by multiple mechanisms. The pneumococcal capsule also alters different 455 
aspects of complement- and phagocyte-mediated immunity, resulting in a profound 456 
inhibition of opsonophagocytosis (19), and effects on the thickness of the capsule layer 457 
could potentially explain the pleiotropic effects of LytA on complement activity. 458 
However, the content of glucuronic acid (a component of the serotype 2 CPS) and the 459 
recognition by specific antibodies to CPS were actually slightly increased for the lytA 460 
mutant. Hence LytA effects on the capsule are unlikely to explain the increased 461 
complement deposition seen on the lytA mutant; in addition the direct interactions of 462 
purified LytA with FH, C4BP, and C3 cannot be explained by effects of loss of LytA on 463 
other aspects of S. pneumoniae biology. Location of bound C3b is important because 464 
the accessibility of this component affects the recognition by phagocytic cells. In this 465 
sense, the opsonic activity of C3b deposited on the bacterial cell wall may be less 466 
efficient to induce phagocytosis. The presence of antibodies to the capsular 467 
polysaccharide (CPS) and the cell wall can also influence complement deposition (49-468 
51). Human sera contain antibodies to multiple S. pneumoniae antigens but these would 469 
not affect our results unless there was marked difference in expression of target antigens 470 
between the strains investigated. Instead, our data indicate that increased complement 471 
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activity against the lytA mutant was mediated by several separate mechanisms 472 
independent of antibodies, including increased Pcho availability (which could be a non-473 
physiological effect of reduced occupation of choline residues in the lytA mutant), direct 474 
binding of LytA to C4BP and FH (causing negative regulation of CP and AP activity 475 
respectively), and enzymatic activity against C3.  476 
AMs are one of the first barriers of the host immune defense system against 477 
pathogens invading the lungs and neutrophils are key players controlling the 478 
dissemination of relevant microorganisms through the systemic circulation (52, 53). 479 
Loss of Ply and LytA was associated with an enhanced uptake of S. pneumoniae by 480 
AMs and neutrophils in vitro, confirming that the effects of these two proteins on 481 
complement are important for avoidance of the recognition and engulfment of S. 482 
pneumoniae by phagocytic cells. This is in agreement with previous evidences showing 483 
synergistic inhibition of complement-dependent immunity and phagocytosis for S. 484 
pneumoniae proteins (21, 27, 54, 55). The efficiency of AMs phagolysosomal 485 
processing and bacterial killing within the macrophage was increased for the ply and 486 
lytA mutants demonstrating that lack of Ply and LytA increases the efficiency of AMs to 487 
clear the bacteria through their phagolysosomal route (56).  488 
Data from the mouse models confirmed that Ply and LytA are critical proteins that 489 
cooperate in the establishment of IPD and pneumonia. Chain length formation has been 490 
identified as a factor that might affect bacterial virulence (39). However, pneumococci 491 
growing as chains due to a lytB mutation did not show impaired virulence in our 492 
models, suggesting that the attenuation in virulence of our lytA mutant was not 493 
significantly related to chain formation (27). Loss of LytA and Ply simultaneously 494 
showed a marked attenuation in virulence, indicating that both proteins cooperate in the 495 
replication of the bacterium in the respiratory tract and systemic circulation. The 496 
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impaired levels of the mutants in the blood, as previously reported (21, 41, 43, 47), 497 
suggest that pneumococcal strains lacking LytA and Ply have a reduced ability to 498 
breach the epithelial barrier. This is in agreement with a previous study showing that 499 
lack of both LytA and Ply had an additive effect in the median survival time in a murine 500 
sepsis model of infection (43), and is a phenotype that has previously been shown to be 501 
related to complement sensitivity for the double ply pspA mutant (21). Overall, our 502 
results confirm that LytA plays an important role in bacteraemic pneumonia and sepsis 503 
by a mechanism that is independent of Ply release, and is likely to reflect the additive 504 
effects seen in vitro of Ply and LytA on complement inhibition and phagocytosis. 505 
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FIGURE LEGENDS 692 
 693 
FIG 1 LytA of S. pneumoniae avoids complement activation by a Ply independent 694 
mechanism. (A) C3b deposition on the surface of the wild-type and isogenic defective 695 
strains using normal human serum (NHS) and measured by flow cytometry assay. (B) 696 
Example of a flow cytometry histogram for C3b deposition using NHS. (C) Deposition 697 
of C3b via AP (white bars) or CP (grey bars) activity in C1q (white bars) or factor B 698 
(grey bars) depleted human sera respectively. (D) Binding to C3b on the surface of the 699 
wild-type D39 and lytB strains. (E) Phase-contrast microscopy images of pneumococcal 700 
wild-type D39 and isogenic lytA and lytB strains. Error bars represent the standard 701 
deviations (SDs) and asterisks indicate statistical significance compared to the wild-type 702 
strain. P < 0.01 for the comparison of the C3b results for lytA ply versus the single 703 
mutants using NHS. For the results for all defective strains compared to wild-type, P < 704 
0.001 (one-way ANOVA with Dunnett’s post hoc test).  705 
 706 
FIG 2 Ply and LytA divert classical pathway activation. (A) Deposition of C1q on the 707 
surface of the different mutants compared to the wild-type strain. (B) Example of a flow 708 
cytometry histogram for C1q deposition. (C) Recognition of the wild-type strain and the 709 
different mutants by CRP. (D) Example of a flow cytometry histogram for CRP 710 
deposition. (E) Pcho levels on the surface of wild-type strains D39 and 1515 of 711 
serotypes (STs) 2 and 6B respectively and LytA-deficient mutants. (F) Example of a 712 
flow cytometry histogram for Pcho level on the ST2 strain. (G) Example of a flow 713 
cytometry histogram for Pcho level on the ST6B strain. Error bars represent the 714 
standard deviations (SDs) and asterisks indicate statistical significance compared to the 715 
wild-type strain. For the results for all defective strains compared to wild-type, P < 716 
0.001 (one-way ANOVA with Dunnett’s post hoc test).  717 
 718 
FIG 3 LytA recruits C4BP to reduce classical pathway activation. (A) Proportion of 719 
bacteria positive for C4BP for the D39 wild-type strain and different mutants. (B) 720 
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Example of a flow cytometry histogram for C4BP binding for the D39 genetic 721 
background strains. (C) Proportion of bacteria positive for C4BP for the S3 lytA mutant 722 
strain and the complemented strain S3C (lytA+) belonging to serotype 23F. (D) Example 723 
of a flow cytometry histogram for C4BP binding for the ST23F strains. (E) Direct 724 
binding of 10 μg/ml of LytA to different concentrations of C4BP by ELISA. Error bars 725 
represent the SDs and asterisks indicate statistical significance of single mutants 726 
compared to the wild-type strain or between different concentrations of C4BP compared 727 
to the absence of protein. P < 0.05 for the comparison of C4BP results between pspC 728 
lytA vs single mutants.  729 
 730 
FIG 4 LytA binds the down-regulator factor H to impair the activation of the alternative 731 
pathway. (A) Proportion of bacteria positive for FH for the D39 wild-type strain and 732 
different mutants. (B) Example of a flow cytometry histogram for FH binding for the 733 
D39 genetic background strains. (C) Proportion of bacteria positive for FH for the S3 734 
lytA mutant strain and the complemented strain S3C (lytA+) belonging to serotype 23F. 735 
(D) Mean Fluorescence Intensity of FH binding on the surface of S3 lytA strain and the 736 
complement S3C (lytA+) strain. (E) Example of a flow cytometry histogram for FH 737 
binding of the ST23F strains. (F) Direct binding of 10 μg/ml of LytA to different 738 
concentrations of FH by ELISA. Error bars represent the SDs and asterisks indicate 739 
statistical significance compared to the wild-type strain or between different 740 
concentrations of FH compared to the absence of protein. P < 0.01 for the comparison 741 
of FH results between pspC lytA vs single mutants.  742 
 743 
FIG 5 PspC levels are similar in the wild-type and lytA strain. (A) PspC levels on the 744 
surface of D39 wild-type strain and LytA-deficient mutant. (B) Example of a flow 745 
cytometry histogram for PspC level. Error bars represent the SDs.  746 
 747 
FIG 6 LytA degrades C3b and iC3b to impair complement activation. (A) Flow 748 
cytometry assay showing degradation of the C3b deposited on lytA strain previously 749 
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opsonized with serum in the presence of 0.3 μg of either LytA amidase, choline-binding 750 
domain of LytA (C-LytA), or a mutated LytA protein without amidase activity 751 
(LytAH133A). Error bars represent the SDs and asterisks indicate statistical significance 752 
compared to the wild-type strain. (B) Coomasie-stained polyacrilamide gel showing 753 
C3b degradation by FH-FI and Western-Blot to detect C3 fragments using a lytA mutant 754 
opsonized with serum (lanes 1-5) and exposed to 3 ng of LytA having amidase activity 755 
(2), LytC lysozyme (3), C-LytA (4) and LytAH133A (5). (C−D) Western-blotting to 756 
detect fragments of C3b and iC3b degradation respectively, after exposure of purified 757 
C3b (C) and iC3b (D) to LytA or LytAH133A. Black triangles mark typical bands of C3b 758 
degradation by FH/FI (α65 and α43) and solid black arrows indicate C3b fragments 759 
obtained after digestion with LytA. (E) Degradation of the C3b deposited on the R6 760 
strain in the presence or absence of 0.3 μg of LytA. 761 
 762 
FIG 7. Evasion of the phagocytosis process mediated by pneumolysin and LytA. (A) 763 
Phagocytosis of FAM-SE labeled wild-type strain and the different mutant strains 764 
incubated in 20% normal human serum using a flow cytometry assay. Results are 765 
expressed as a percent fluorescent index relative to the results for the wild-type D39 766 
strain. (B) Example of a flow cytometry histogram for phagocytosis by neutrophils. (C) 767 
Opsonophagocytosis of the different strains expressing the GFP protein by human 768 
neutrophils detected by confocal microscopy. DNA was stained by Hoechst and actin 769 
cytoskeleton was visualized with Rhodamine-Phalloidin (RRX) staining. (D) 770 
Attachment to AMs of the different mutant strains compared to the wild-type strain at 1 771 
h post-infection. (E−F) Phagocytosis of the different strains by AMs at 1 h and 4 h post-772 
infection respectively. (G) Phagolysosomal maturation of AMs during infection with S. 773 
pneumoniae lytA ply expressing the GFP. DNA was stained with Hoechst whereas late 774 
endosomal markers were visualized using specific antibodies to recognize LAMP-1 and 775 
LAMP-2. Error bars represent the SDs and asterisks indicate statistical significance 776 
compared to the wild-type strain. P <0.01 for the comparison of the phagocytosis results 777 
for  lytA ply versus the single mutants except for 4h phagocytosis of AMs between  lytA 778 
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ply vs lytA (P =0.21). For the results for all defective strains compared to wild-type, P 779 
<0.001 (one-way ANOVA with Dunnett’s post hoc test). 780 
 781 
FIG 8. Role of Ply and LytA in the establishment of sepsis (intraperitoneal inoculation) 782 
and pneumococcal pneumonia (intranasal inoculation). (A) Bacterial levels recovered 783 
from blood at 24 h after pneumococcal sepsis produced with the wild-type and mutant 784 
strains. (B−D) Bacterial levels recovered at 24 h from BAL (B), lung homogenate (C) 785 
and blood (D) after pneumonia infection with the wild-type and defective strains. Error 786 
bars represent the SDs and asterisks indicate statistical significance of bacterial levels of 787 
the different mutant strains compared to the wild-type strain. P <0.05 for the 788 
comparison of bacterial levels for lytA ply versus the single mutants. For the results for 789 
all defective strains compared to wild-type, P <0.01 (one-way ANOVA with Dunnett’s 790 
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